Genprex (NASDAQ:GNPX) Shares Up 0.9% – Still a Buy?

Genprex (NASDAQ:GNPX) rose 0.9% during trading on Monday . The stock traded as high as $3.65 and last traded at $3.48. 116,474 shares traded hands during mid-day trading, an increase of 143% from the average daily volume of 47,903 shares. The stock had previously closed at $3.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a report on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Genprex has a consensus rating of “Sell”.

Genprex Trading Up 5.9%

The stock’s 50-day moving average is $4.88 and its 200-day moving average is $16.83. The stock has a market cap of $3.08 million, a P/E ratio of -0.03 and a beta of -0.94.

Genprex (NASDAQ:GNPX) last announced its earnings results on Friday, August 14th. The company reported ($9.40) EPS for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Genprex stock. Mayflower Financial Advisors LLC purchased a new stake in Genprex (NASDAQ:GNPX) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 20,000 shares of the company’s stock, valued at approximately $36,000. Mayflower Financial Advisors LLC owned about 0.22% of Genprex at the end of the most recent quarter. 14.05% of the stock is owned by institutional investors and hedge funds.

About Genprex

Genprex, Inc is a clinical-stage biotechnology company focused on developing gene therapies for cancer and other serious diseases. The company’s technology is designed to deliver therapeutic genes into cells using a nonviral delivery system, with the goal of restoring tumor-suppressor activity or producing other disease-fighting effects.

Genprex’s lead product candidate is REQORSA® Immunogene Therapy (quaratusugene ozeplasmid), an investigational gene therapy being developed primarily for non-small cell lung cancer.